Showing 2491-2500 of 2652 results for "".
- iSTAR Medical’s MINIject Shows Consistent Results at 18-Month Follow-Up in First-in-Human Trial (STAR-I)https://modernod.com/news/istar-medicals-miniject-shows-consistent-results-at-18-month-follow-up-in-first-in-human-trial-star-i/2476718/iSTAR Medical SA announced consistent 18-month results of the first-in-human, micro-invasive glaucoma surgery (MIGS) STAR-I trial for the MINIject device in a standalone setting. These results confirm the stability and sustained performance of MINIject beyond the first year, according to a compan
- Roche, Spark Push Back Takeover Deadline in $4.3 Billion Dealhttps://modernod.com/news/roche-spark-push-back-takeover-deadline-in-4-3-billion-deal/2479565/Roche and Spark Therapeutics agreed to extend the deadline for the Swiss drugmaker’s $4.3 billion takeover bid for the U.S. gene therapy specialist, Roche said, adding it remains “fully committed” to a deal it sees closing this year, according to a Reuters
- VSP Global Enters Into Definitive Agreement To Acquire Visionworkshttps://modernod.com/news/vsp-global-enters-into-definitive-agreement-to-acquire-visionworks/2476699/VSP Global announced that it has entered into a definitive agreement to acquire San Antonio, Texas-based Visionworks, which has more than 700 stores in 40 states. The Visionworks acquisition will be the single largest VSP network investment in the company’s
- Alan R. Morse, JD, PhD, Vision and Healthcare Services Innovator, Will Retire As President & CEO of Lighthouse Guildhttps://modernod.com/news/alan-r-morse-jd-phd-vision-and-healthcare-services-innovator-will-retire-as-president-ceo-of-lighthouse-guild/2476695/James M. Dubin, Chairman of the Board of Lighthouse Guild, announced that Alan R. Morse, JD, PhD, will be stepping down later this year as President & CEO of Lighthouse Guild after an extraordinary career of almost 52 years as a leader and innovator in the field
- VSY Biotechnology is Now Accepting Applications for the “Ophthalmology Star Awards”https://modernod.com/news/vsy-biotechnology-is-now-accepting-applications-for-the-ophthalmology-star-awards/2476689/The Stars of Ophthalmology will be selected among the applicants who have a scientific article published in an ophthalmology journal since January 2018, according to a VSY Biotechnology news release. The articles are required to be authored in English and already published in order to be eligible
- Alcon’s iLUX MGD Treatment System Wins Top Honor in 2019 Medical Design Excellence Awards (MDEA)https://modernod.com/news/alcons-ilux-mgd-treatment-system-wins-top-honor-in-2019-medical-design-excellence-awards-mdea/2476678/Alcon was selected as a Gold winner for its personalized iLUX MGD Treatment System at the 2019 Medical Design Excellence Awards (MDEA). The award was given in the “Nonsurgical Hospital Supplies and Equipment” category during an event held on June 11 in New York City. Products w
- RightEye, USA Baseball and Optometrists Team Up to Improve Players’ Athletic Abilities Through Sports Visionhttps://modernod.com/news/righteye-usa-baseball-and-optometrists-team-up-to-improve-players-athletic-abilities-through-sports-vision/2476677/RightEye announced that it is working with USA Baseball for the third consecutive year to provide baseline sports vision assessment to all athletes entering the Prospect Development Pipeline (PDP), a collaboration bet
- NovaBay Pharmaceuticals Appoints Justin Hall President and CEO, and Jason Raleigh CFOhttps://modernod.com/news/novabay-pharmaceuticals-appoints-justin-hall-president-and-ceo-and-jason-raleigh-cfo/2476666/NovaBay Pharmaceuticals announced the appointments of Justin Hall as President and Chief Executive Officer, and Jason Raleigh as Chief Financial Officer. Mr. Hall has served as interim President and CEO, and Mr. Raleigh as interim CFO since March 2019. “Justin and Jason have proven their l
- Santen Publishes New Data in Glaucoma and Dry Eye Drug Candidateshttps://modernod.com/news/santen-publishes-new-data-in-glaucoma-and-dry-eye-drug-candidates/2476660/Santen EMEA shared the preliminary results of its two real world evidence (RWE) studies, VISIONARY and PERSPECTIVE, at this year’s European Society of Ophthalmology (SOE) congress. The studies assessed the impact of the effectiveness, tolerability, and safety of topical preservative-free taflupro
- Ribomic Announces Positive Topline Results from the Phase 1/2a Clinical Trial of RBM-007 (SUSHI Study) in Subjects with Wet AMDhttps://modernod.com/news/ribomic-announces-positive-topline-results-from-the-phase-1-2a-clinical-trial-of-rbm-007-sushi-study-in-subjects-with-wet-amd/2476656/Ribomic announced positive topline results from its SUSHI study, a phase 1/2a single ascending dose clinical study of RBM-007, anti-FGF2 aptamer, in nine subjects with wet age-related macular degeneration (AMD). The SUSHI study achiev